Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Acquired by Providence Wealth Advisors LLC

Providence Wealth Advisors LLC increased its stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 29.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,500 shares of the biotechnology company’s stock after purchasing an additional 22,250 shares during the quarter. Providence Wealth Advisors LLC’s holdings in Seres Therapeutics were worth $93,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of MCRB. Point72 DIFC Ltd acquired a new position in Seres Therapeutics during the 2nd quarter worth $64,000. Virtu Financial LLC acquired a new position in Seres Therapeutics during the 1st quarter worth $73,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Seres Therapeutics during the 2nd quarter worth $92,000. Vontobel Holding Ltd. acquired a new position in Seres Therapeutics during the 3rd quarter worth $374,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after purchasing an additional 222,771 shares in the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Trading Up 4.3 %

MCRB stock opened at $0.92 on Friday. The company has a market capitalization of $156.23 million, a P/E ratio of -3.98 and a beta of 2.06. Seres Therapeutics, Inc. has a twelve month low of $0.54 and a twelve month high of $2.05. The business has a 50 day simple moving average of $0.81 and a 200-day simple moving average of $0.90.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MCRB. Chardan Capital reaffirmed a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a report on Wednesday, November 13th. StockNews.com cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. JPMorgan Chase & Co. cut shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.